Clinical trial
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received…
NCT00269477 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00269477 |
|---|---|
| Title | Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® |
| Official title | Persistence of Bactericidal Antibodies in Adolescents and Adults Aged 15 to 23 Years Who Received a Single Dose of Menactra® or Menomune®-A/C/Y/W-135 Five Years Earlier |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Meningitis, Meningococcal Infection |
| Intervention type | Biological |
| Interventions | Meningococcal Polysaccharide Diphtheria Toxoid Conjugate |
| Enrollment | 145 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Dec 23, 2005 |
| Last update posted | Apr 14, 2016 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: